Vaccinex will receive a technology access fee and research funding and is eligible for milestone payments and royalties. Following the initial research phase, Vaccinex may receive certain options to co-develop a selected cancer product with Schering AG. Financial details of the deal were not disclosed.
“We are very excited about applying our proprietary technologies to validate several of Schering AG’s oncology targets as well as to have an opportunity to collaborate in co-developing a promising cancer product,” commented Dr Maurice Zauderer, president and CEO of Vaccinex.
Using its proprietary vaccinia vector technology, Vaccinex has developed a library-based discovery platform capable of identifying novel antigens and of selecting fully human monoclonal antibodies against disease targets.